ROVI 9M 2026 Net Profit Jumps 67% Year-on-Year to EUR 162.8 Million

By Public Technologies
  • ROVI’s net profit rose 67% year over year to EUR 162.8 million in the first nine months of 2026.
  • Revenue climbed 16% year over year to EUR 610.2 million.
  • Results included a EUR 62.4 million nonrecurring bargain-purchase gain from the acquisition of the Phoenix manufacturing plant.
  • ROVI raised its 2026 revenue growth outlook to mid-to-high single digits, citing stronger expected contract manufacturing growth and higher bemiparin partner volumes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Farmacéuticos ROVI SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk